Author:
Zografos Laurie J.,Andrews Elizabeth,Wolin Daniel L.,Calingaert Brian,Davenport Eric K.,Hollis Kelly A.,Schmidt-Ott Ursula Maria,Petraro Paul,Vassilev Zdravko P.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference20 articles.
1. European Medicines Agency (EMA). Eylea summary of product characteristics. September 8, 2016.
https://www.medicines.org.uk/emc/medicine/27224
. Accessed 22 Feb 2017.
2. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(5):647–56.
3. Jeganathan VS, Verma N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol. 2009;20(3):223–5.
4. European Medicines Agency (EMA). Assessment report: Eylea (aflibercept). July 25, 2013.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002392/WC500148631.pdf
. Accessed 31 Aug 2017.
5. International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Revision 3. International Society for Pharmacoepidemiology; June 2015.
http://www.pharmacoepi.org/resources/guidelines_08027.cfm
. Accessed 24 May 2016.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献